Dissecting the function of cytochrome P450

被引:20
作者
Boobis, AR
Edwards, RJ
Adams, DA
Davies, DS
机构
关键词
P450; antibodies; protein structure; inhibition; immunological analysis; drug metabolism; human liver; peptides;
D O I
10.1046/j.1365-2125.1996.37912.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The role that P450 plays in the metabolism of drugs and other chemicals is often pivotal in determining the duration and magnitude of their biological effects, so that it is important to identify the specific forms of the enzyme involved. 2 The similarity between different forms of P450 is such that polyclonal antibodies raised by conventional means, even against a homogeneous preparation of the enzyme will often react with several different P450s. 3 Whilst monoclonal antibodies are often more specific, their selectivity cannot be determined prior to their use. 4 The use of short sequences of amino acids (4-7 residues) predicted to occur in surface loop regions of the protein as immunogens, affords a means of targeting antibodies to specific forms of P450. 5 The terminal amino acid of a peptide, here the C-terminal residue, is very immunodominant in determining the specificity of the resultant antibody. Hence, antibodies against the C-terminal residues of P450 have a high affinity and, in most cases, will be specific. 6 Application of anti-peptide antibodies to the major forms of P450 in human liver revealed the anticipated interindividual variation. However, evidence was found that the polymorphism in CYP3A5 expression is quantitative rather than qualitative. 7 A putative pro-inhibitory region on the surface of mammalian P450, possibly involved in intramolecular electron transport, has been identified, using a combination of directed anti-peptide antibodies and sequence alignment based on secondary structure. 8 Antibodies directed against defined regions of P450 enzymes are proving invaluable in exploring the regulation, specificity and function of these key enzymes.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 67 条
  • [1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
    ALVAN, G
    BECHTEL, P
    ISELIUS, L
    GUNDERTREMY, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
  • [2] ARCHAKOV AI, 1993, BIOCHEM MOL BIOL INT, V31, P1071
  • [3] BOOBIS A R, 1985, British Journal of Pharmacology, V86, p511P
  • [4] A MONOCLONAL-ANTIBODY RAISED TO RAT-LIVER CYTOCHROME-P-448 (FORM-C) WHICH RECOGNIZES AN EPITOPE COMMON TO MANY OTHER FORMS OF CYTOCHROME-P-450
    BOOBIS, AR
    MCQUADE, J
    SESARDIC, D
    ROBSON, RT
    HAYWARD, C
    LOCK, EA
    ELCOMBE, CR
    ROSE, MS
    DAVIES, DS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1985, 34 (10) : 1671 - 1681
  • [5] MONOCLONAL-ANTIBODIES TO RABBIT LIVER CYTOCHROME P-448
    BOOBIS, AR
    SLADE, MB
    STERN, C
    LEWIS, KM
    DAVIES, DS
    [J]. LIFE SCIENCES, 1981, 29 (14) : 1443 - 1448
  • [6] MONO-OXYGENASE ACTIVITY OF HUMAN-LIVER IN MICROSOMAL FRACTIONS OF NEEDLE-BIOPSY SPECIMENS
    BOOBIS, AR
    BRODIE, MJ
    KAHN, GC
    FLETCHER, DR
    SAUNDERS, JH
    DAVIES, DS
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (01) : 11 - 19
  • [7] COMMERCIALIZATION OF GENE-THERAPY - THE EVOLUTION OF LICENSING AND RIGHTS ISSUES
    BOSSART, J
    PEARSON, B
    [J]. TRENDS IN BIOTECHNOLOGY, 1995, 13 (08) : 290 - 294
  • [8] DRUG-METABOLISM IN WHITE VEGETARIANS
    BRODIE, MJ
    BOOBIS, AR
    TOVERUD, EL
    ELLIS, W
    MURRAY, S
    DOLLERY, CT
    WEBSTER, S
    HARRISON, R
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (05) : 523 - 525
  • [9] CANCER GENES - SINGLE AND SUSCEPTIBILITY - EXPOSING THE DIFFERENCE
    CAPORASO, N
    GOLDSTEIN, A
    [J]. PHARMACOGENETICS, 1995, 5 (02): : 59 - 63
  • [10] EVIDENCE FOR AN ENZYMATIC DEFECT IN THE 4-HYDROXYLATION OF DEBRISOQUINE BY HUMAN-LIVER
    DAVIES, DS
    KAHN, GC
    MURRAY, S
    BRODIE, MJ
    BOOBIS, AR
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (01) : 89 - 91